Those engaging in this treatment often report reduced appetite, earlier satiety, increased energy levels, and improvement in conditions associated with weight loss like high blood pressure
Large-scale trials of semaglutide and tirzepatide have demonstrated sustained weight reductions approaching 1522% of baseline body weight in adults with overweight and obesity [1][2][3]
Coverage for weight management or obesity treatment can be more variable, as not all insurance plans include benefits for weight loss medications
It can quietly progress for years while a person feels increasingly numb, tired, forgetful, and unlike themselves
Despite psoas muscle volume loss during 24 weeks of the trial, chair rise time and one measure of gait speed did not change significantly
Local NSCs are identified by their astrocytic molecular characteristics (e.g., expression of glial fibrillary acidic protein, GFAP) and radial glia-like (RGL) morphology, resembling embryonal neural progenitors, and have the capacity for self-renewal and multipotency (Figure 1E)